8 terminated. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 3 | 1 | Terminated 1 |
Follow Nephrosis: new trials by email Literature Review of Nephrosis trials Research Report on Nephrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases GFB-887 - Kidney Diseases, Glomerulosclerosis | Phase 2 | Terminated | Goldfinch Bio, Inc. | 31 | 2021-07-27 | 2022-11-15 |
| A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease GFB-887, Placebo - Kidney Diseases, Diabetic Nephropathies | Phase 2 | Terminated | Goldfinch Bio, Inc. | 96 | 2020-07-28 | 2022-11-15 |
| Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome Rituximab Biosimilar, Mycophenolate Mofetil - Nephrotic Syndrome Steroid-Dependent | Phase 2 | Terminated | Istituto Giannina Gaslini | 30 | 2019-07-01 | 2020-09-14 |
| Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome Alirocumab, Alirocumab placebo, Atorvastatin - Nephrotic Syndrome | Phase 2 | Terminated | Gloria Vega | 3 | 2017-01-01 | 2022-08-19 |
| Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. Enoxaparin - Nephrotic Syndrome | Phase 2 / Phase 3 | Terminated | Military Institute od Medicine National Research Institute | 65 | 2015-10-01 | 2023-01-30 |
| Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome Ofatumumab, Placebo - Nephrotic Syndrome | Phase 2 | Terminated | Istituto Giannina Gaslini | 13 | 2015-07-01 | 2020-07-29 |
| Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome Atorvastatin, Placebo - Nephrotic Syndrome, Hyperlipidemia | Phase 2 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 | 1998-10-01 | 2017-09-15 |
Nephrotic Syndrome (5) · Glomerulonephritis (2) · Glomerulosclerosis, Focal Segmental (2) · Kidney Diseases (2) · Nephritis (2) · Nephrosis, Lipoid (2) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Nephropathies (1) · Dyslipidemias (1) · Endocrine System Diseases (1) · Hyperlipidemias (1) · Proteinuria (1) · Rare Diseases (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Male Urogenital Diseases (8) · Urogenital Diseases (7) · Urologic Diseases (7) · Kidney Diseases (6) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Lipid Metabolism Disorders (2) · Pathological Conditions, Signs and Symptoms (2) · Cardiovascular Diseases (1) · Disease Attributes (1) · Dyslipidemias (1) · Embolism and Thrombosis (1)
Atorvastatin (2) · Enoxaparin (1) · Mycophenolic Acid (1) · Saline Solution (1) · alirocumab (1) · ofatumumab (1)
Goldfinch Bio, Inc. (2) · Istituto Giannina Gaslini (2) · Gloria Vega (1) · Military Institute od Medicine National Research Institute (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Tenet Medicines (1)
United States (5) · Italy (2) · Poland (1)
Gianmarco Ghiggeri, MD (2) · Anna Matyjek, MD, PhD (1) · Gloria L Vega, PhD (1) · Michael Concepcion, MD (1) · Ronald Hogg (1) · Yin Oo, MD (1)
PMID 31993781, PMID 33616641, PMID 34884411, PMID 38724717, PMID 39513526, PMID 40337980
R21DK053611 (1)